Home » Authors » Cynthia Robbins-Roth

Articles by Cynthia Robbins-Roth

Maybe It's Time to Reinvent Bio's Entrepreneurial Spirit

Feb. 4, 2008

By Cynthia Robbins-Roth

Merckifying Genentech And Other Bio Rhythms

Dec. 10, 2007

By Cynthia Robbins-Roth

Merckifying Genentech And Other Bio Rhythms

Dec. 10, 2007

By Cynthia Robbins-Roth

Name (Changing) Game Is An Old Biotech Trick

Nov. 12, 2007

By Cynthia Robbins-Roth

Name (Changing) Game Is An Old Biotech Trick

Nov. 12, 2007

By Cynthia Robbins-Roth

Academia May Be Suffering But Biotech Chugs Along

Oct. 8, 2007

By Cynthia Robbins-Roth

Academia May Be Suffering But Biotech Chugs Along

Oct. 8, 2007

By Cynthia Robbins-Roth

Revenge of the Entrepreneurs: See It Now At TheFunded.com

Sep. 10, 2007

By Cynthia Robbins-Roth

Revenge of the Entrepreneurs: See It Now At TheFunded.com

Sep. 10, 2007

By Cynthia Robbins-Roth

Why Do It? Because We Can! Favorite Stupid Biotech Tricks

Aug. 13, 2007

By Cynthia Robbins-Roth

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 4, 2024.
In muscular dystrophies, gene therapies race the clock
BioWorld
Since the isolation of the gene that causes Duchenne muscular dystrophy (DMD), scientists have progressed in understanding the mechanisms that lead to muscular...
Bridgebio, with FDA approval, faces Pfizer in ATTR
BioWorld
With the U.S. FDA approval of Attruby (acoramidis) for transthyretin amyloidosis with cardiomyopathy (ATTR-CM), Bridgebio Pharma Inc. is taking on an industry...
Phase III AMD miss leaves BLA Outlook same with bevacizumab
BioWorld
Outlook Therapeutics Inc. is forging onward with plans to resubmit the BLA for ONS-5010, an ophthalmic version of Avastin (bevacizumab, Roche AG), after a missed...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.